Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jacob J. Adashek"'
Autor:
Karlton Wong, Fritz C. Eilber, Sarah M. Dry, Mark A. Eckardt, Jomjit Chantharasamee, Jacob J. Adashek, Arun S. Singh, Bartosz Chmielowski
Publikováno v:
Current Treatment Options in Oncology. 22
The role of targeted therapy is firmly established for gastrointestinal stromal tumors (GISTs); other modalities for targeting this disease are necessary for recurrent and refractory disease. There are several lines of evidence pointing to an active
Autor:
David Redding, Jacob J. Adashek
Publikováno v:
Cureus
Background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the United States and changes in lifestyle can minimize the likelihood of succumbing to heart disease. Anti-inflammatory agents are commonly used to reduce the
Autor:
Jad Chahoud, Anthony M. Magliocco, Mounsif Azizi, Andrea Necchi, Jeffrey S. Ross, Philippe E. Spiess, Ahmet M. Aydin, Jacob J. Adashek
The incidence of penile squamous cell carcinoma (PSCC) has increased in developed countries over the past decades owing to increased human papilloma virus (HPV) exposure. Despite successful surgical treatment of locoregional PSCC, effective treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96b56b08bedfdb57815f3d120a967d2
Autor:
Ignacio Matos, Elena Garralda, Arjun K. Menta, Jacob J. Adashek, Dhakshinamoorthy Ganeshan, Vivek Subbiah, Ishwaria Mohan Subbiah
Publikováno v:
Trends in cancer. 6(3)
Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who do not benefit from IO, instead experiencing rapid progression with dramatic acceleration of
Publikováno v:
Genome Medicine
Genome medicine, vol 12, iss 1
Genome Medicine, Vol 12, Iss 1, Pp 1-19 (2020)
Genome medicine, vol 12, iss 1
Genome Medicine, Vol 12, Iss 1, Pp 1-19 (2020)
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures. Intriguingly, rapidly emerging data indicate that altered genes represent
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 2, Pp 276-280 (2018)
Case Reports in Oncology
Case Reports in Oncology
This case represents the challenge and creativity necessary when treating patients with metastatic renal cell carcinoma who have been exposed to multiple lines of therapy. At present, treatment with immune checkpoint inhibition has stabilized and imp
Autor:
Manuel Caitano Maia, Paulo Gustavo Bergerot, Sumanta K. Pal, Simone Fernandes dos Santos, Lorena Almeida, Jacob J. Adashek
Publikováno v:
Journal of Geriatric Oncology. 9:265-274
Physiological changes that occur during the aging process may impact drug metabolism and availability, consequently affecting treatment efficacy and tolerability. Despite being a disease of older adults, there is little data to guide treatment decisi
Publikováno v:
Kidney Cancer
The treatment of metastatic renal cell carcinoma (mRCC) has evolved markedly over the past several decades; first with the introduction of targeted therapies and more recently with data supporting checkpoint inhibition. However, the vast majority of
Publikováno v:
Urologic oncology. 37(7)
Penile cancer is a rare, but increasingly more common diagnosis. Although more there are more cases of penile cancer being diagnosed (the incidence is increasing), mortality (or conversely overall survival) has not changed. A detailed discussion of c
Publikováno v:
Cancer Research. 80:6473-6473
Background: Cytoreductive nephrectomy in the setting of treatment of advanced renal cell carcinoma with sarcomatoid features (sRCC) has been highly contested in terms of added benefit for survival. Patients with sRCC are known to have a poor prognosi